text_1: V-9302 inhibits antitumor responses by decreasing cell death and oxidative stress.
text_2: This is the first study, to our knowledge, to demonstrate the utility of a pharmacological inhibitor of glutamine transport in oncology, representing a new class of targeted therapy and laying a framework for paradigm-shifting therapies targeting cancer cell metabolism.